AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
December 12, 2022 09:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
December 08, 2022 08:05 ET
|
AIM ImmunoTech Inc.
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral...
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
December 02, 2022 10:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
November 14, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete...
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
November 02, 2022 07:05 ET
|
AIM ImmunoTech Inc.
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune...
AIM ImmunoTech宣布获FDA授予IND申请批准，以评估安普利近®用于治疗新冠病毒感染后遗症的2期临床研究
October 13, 2022 04:47 ET
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, Oct. 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所股票代码：American...
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
October 12, 2022 16:32 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
October 12, 2022 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
September 21, 2022 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...